Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Wells, A. U.; Flaherty, K. R.; Brown, K. K.et al.
2020 • In The Lancet Respiratory Medicine, 8 (5), p. 453-460
Wells, A. U.; National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom
Flaherty, K. R.; Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, United States
Brown, K. K.; Department of Medicine, National Jewish Health, Denver, CO, United States
Inoue, Y.; Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan
Devaraj, A.; Department of Radiology, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom, National Heart and Lung Institute, Imperial College, London, United Kingdom
Richeldi, L.; Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
Moua, T.; Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, United States
Crestani, B.; Université de Paris, Inserm U1152, APHP, Hôpital Bichat, Centre de reference constitutif pour les maladies pulmonaires rares, Paris, France
Wuyts, W. A.; Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium
Stowasser, S.; Boehringer Ingelheim International, Ingelheim am Rhein, Germany
Quaresma, M.; Boehringer Ingelheim International, Ingelheim am Rhein, Germany
Schlenker-Herceg, R.; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States
Kolb, M.; McMaster University and St Joseph's Healthcare, Hamilton, Ontario, Canada
Abe, S.
Aburto, M.
Acosta, O.
Andrews, C.
Antin-Ozerkis, D.
Arce, G.
Arias, M.
Avdeev, S.
Barczyk, A.
Bascom, R.
Bazdyrev, E.
Beirne, P.
Belloli, E.
Bergna, M. A.
Bergot, E.
Bhatt, N.
Blaas, S.
Bondue, B.
Bonella, F.
Britt, E.
Buch, K.
Burk, J.
Cai, H.
Cantin, A.
Castillo Villegas, D. M.
Cazaux, A.
Cerri, S.
Chaaban, S.
Chaudhuri, N.
Cottin, V.
Crestani, B.; Université de Paris, Inserm U1152, APHP, Hôpital Bichat, Centre de reference constitutif pour les maladies pulmonaires rares, Paris, France
Criner, G.
Dahlqvist, Carl-Henrik ; Université de Liège - ULiège > Département d'astrophys., géophysique et océanographie (AGO) > PSILab
Danoff, S.
Dematte D'Amico, J.
Dilling, D.
Elias, P.
Ettinger, N.
Falk, J.
Fernández Pérez, E. R.
Gamez-Dubuis, A.
Giessel, G.
Gifford, A.
Glassberg, M.
Glazer, C.
Golden, J.
Gómez Carrera, L.
Guiot, Julien ; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie
Hallowell, R.
Hayashi, H.
Hetzel, J.
Hirani, N.
Homik, L.
Hope-Gill, B.
Hotchkin, D.
Ichikado, K.
Ilkovich, M.
Inoue, Y.
Izumi, S.
Jassem, E.
Jones, L.
Jouneau, S.
Kaner, R.
Kang, J.
Kawamura, T.
Kessler, R.
Kim, Y.
Kishi, K.
Kitamura, H.
Kolb, M.
Kondoh, Y.
Kono, C.
Koschel, D.
Kreuter, M.
Kulkarni, T.
Kus, J.
Lebargy, F.
León Jiménez, A.
Luo, Q.
Mageto, Y.
Maher, T. M.
Makino, S.
Marchand-Adam, S.
Marquette, C.
Martinez, R.
Martínez, M.
Maturana Rozas, R.
Miyazaki, Y.
Moiseev, S.
Molina-Molina, M.
Morrison, L.
Morrow, L.
Moua, T.; Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, United States
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Wells, AU, Brown, KK, Flaherty, KR, Kolb, M, Thannickal, VJ, What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J, 51, 2018, 1800692.
Cottin, V, Wollin, L, Fischer, A, Quaresma, M, Stowasser, S, Harari, S, Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev, 28, 2019, 180100.
Kolb, M, Vašáková, M, The natural history of progressive fibrosing interstitial lung diseases. Respir Res, 20, 2019, 57.
Adegunsoye, A, Oldham, JM, Chung, JH, et al. Phenotypic clusters predict outcomes in a longitudinal interstitial lung disease cohort. Chest 153 (2018), 349–360.
Kim, MY, Song, JW, Do, KH, Jang, SJ, Colby, TV, Kim, DS, Idiopathic nonspecific interstitial pneumonia: changes in high-resolution computed tomography on long-term follow-up. J Comput Assist Tomogr 36 (2012), 170–174.
Hyldgaard, C, Hilberg, O, Pedersen, AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76 (2017), 1700–1706.
Patterson, KC, Strek, ME, Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc 10 (2013), 362–370.
Zamora-Legoff, JA, Krause, ML, Crowson, CS, Ryu, JH, Matteson, EL, Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 69 (2017), 542–549.
Hoffmann-Vold, AM, Fretheim, H, Halse, AK, et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am J Respir Crit Care Med 200 (2019), 1258–1266.
Solomon, JJ, Chung, JH, Cosgrove, GP, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 47 (2016), 588–596.
Gimenez, A, Storrer, K, Kuranishi, L, Soares, MR, Ferreira, RG, Pereira, CAC, Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax 73 (2018), 391–392.
Goh, NS, Hoyles, RK, Denton, CP, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 69 (2017), 1670–1678.
Shah, SJ, Innovative clinical trial designs for precision medicine in heart failure with preserved ejection fraction. J Cardiovasc Transl Res 10 (2017), 322–336.
Tao, JJ, Schram, AM, Hyman, DM, Basket studies: redefining clinical trials in the era of genome-driven oncology. Annu Rev Med 69 (2018), 319–331.
Wollin, L, Distler, JHW, Redente, EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J, 54, 2019, 1900161.
Wollin, L, Wex, E, Pautsch, A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 45 (2015), 1434–1445.
Richeldi, L, du Bois, RM, Raghu, G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2071–2082.
Distler, O, Highland, KB, Gahlemann, M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380 (2019), 2518–2528.
Flaherty, KR, Brown, KK, Wells, AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res, 4, 2017, e000212.
Flaherty, KR, Wells, AU, Cottin, V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381 (2019), 1718–1727.
Lynch, DA, Sverzellati, N, Travis, WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 6 (2018), 138–153.
Travis, WD, Costabel, U, Hansell, DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188 (2013), 733–748.
Ryerson, CJ, Urbania, TH, Richeldi, L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 42 (2013), 750–757.
Walsh, SLF, Lederer, DJ, Ryerson, CJ, et al. Diagnostic likelihood thresholds that define a working diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 200 (2019), 1146–1153.
Lancaster, L, Crestani, B, Hernandez, P, et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res, 6, 2019, e000397.